Clinical Trials Browser

amivantamab × Other solid neoplasm × 90 days × Clear all

NCT06816992 2026-04-24

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Phase 1 Recruiting

Other solid neoplasmThoracic

Solid Tumors